Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab

Published:2004-01-14 Issue:4 Volume:31 Page:547-554
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Beyer G.-J.,Miederer M.,Vranješ-Đurić S.,Čomor J. J.,Künzi G.,Hartley O.,Senekowitsch-Schmidtke R.,Soloviev D.,Buchegger F.,

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-003-1413-9.pdf

Reference28 articles.

1. Hall EJ. Radiobiology for the radiologist. 4th edn. Philadelphia: Lippincott, 1994.

2. Maecklis RM, Lin JY, Beresford B, Achter RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: inducing of apoptosis. Radiat Res 1992; 130:220–226.

3. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg D. Design of225Ac-radiopharmaceuticals. Appl Rad Isot 2002; 57:841–847.

4. Allen BJ, Blagojevic N. Alpha and beta emitting radiolanthanides in targeted cancer therapy: the potential role for terbium-149. Nucl Med Commun 1996; 17:40–47.

5. Zalutsky MR, Vaidyanathan G. Astatine-211 labeled radiotherapeuticals: an emerging approach to targeted alpha particle therapy. Current Pharm Design 2000; 6:1433–1455.

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH;Nuclear Medicine and Biology;2024-09

2. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals;PET Clinics;2024-07

3. Terbium-149 production: a focus on yield and quality improvement towards preclinical application;Scientific Reports;2024-02-08

4. Actinium-225 targeted alpha particle therapy for prostate cancer;Theranostics;2024

5. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside;Theranostics;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3